Skip to content

The development of new treatment for depression by neurofeedback.

Randomized controlled trial of the development of new treatment for depression using neurofeedback based on neuroimaging biomarkers.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs062190030
Enrollment
40
Registered
2020-01-30
Start date
2020-04-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression

Interventions

A one-day NFB session takes about 45 minutes. The sessions are conducted 5 times within 2 weeks.

Sponsors

Okamoto Yasumasa
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1)Patients aged 20 years and over,under 80 years (outpatient or hospitalized patient). (2)Subjects are diagnosed with major depressive disorder according to DSM-TR or DSM-5. (3)Currently subjects meet diagnostic criteria for major depressive episodes (according to M.I.N.I.). (4)In the latest major depressive episodes,with treatment-resistant(HRSD score is 14 points or more with sufficient doses of antidepressants for 4 weeks or more) or with treatment low tolerance(impossible to take in adequate amount antidepressants by serious side effects). (5)Signed informed consent by oneself.

Exclusion criteria

Exclusion criteria: (1)Incapability to understand the purpose of the study. (2)Impossible to examine on the ground of serious illness. (3)It`s difficult for subjects below to get an MRI. - With an implanted cardiac pacemaker. - With a brain vascular clip. - Users of a nerve electrical stimulator. - With an implanted pump in one's body. - With a piece of metal in one's body. - With tattoos (including permanent makeup etc). - Pregnancy or possibly pregnant. - MRI claustrophobia. (4)Those participating in other intervention studies.

Design outcomes

Primary

MeasureTime frame
Hamilton Rating Scale for Depression(HRSD) Beck Depression Inventory(BDI-II) The Positive and Negative Affect Schedule(PANAS)

Secondary

MeasureTime frame
Rumination Reflection Questionnaire(RRQ) Ruminative Response Scale(RRS)

Contacts

Public ContactGo Okada

Hiroshima University Hospital

goookada@hiroshima-u.ac.jp+81-82-257-5814

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026